VITAL THERAPIES Forum: Community User: Maroni
NEW YORK, November 7, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2023, including a corporate update, on Tuesday, November 14, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_AxIAE0pCQ12oMZIiehNKDg or on the “Events and Presentations” section of Immunic’s website at: ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access. An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations.
|
|
Thema | ||
|---|---|---|---|
| 1 | DAX / Germany 40 Hauptdiskussion | +0,49 % | |
| 2 | DAX Prognose / Germany 40 | +0,49 % | |
| 3 | ATOS Hauptdiskussion | -1,04 % | |
| 4 | NVIDIA Hauptdiskussion | +0,56 % | |
| 5 | SAP Hauptdiskussion | -1,21 % | |
| 6 | für alle, die es ehrlich meinen beim Traden. | ||
| 7 | ORACLE Hauptdiskussion | -0,54 % | |
| 8 | HELLOFRESH SE INH O.N. Hauptdiskussion | +0,07 % | |
| 9 | Trading- und Aktien-Chat | ||
| 10 | Quantum Crypto Security | ±0,00 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | ATOS Hauptdiskussion | -1,04 % | |
| 2 | NVIDIA Hauptdiskussion | +0,56 % | |
| 3 | SAP Hauptdiskussion | -1,21 % | |
| 4 | ORACLE Hauptdiskussion | -0,54 % | |
| 5 | Quantum Crypto Security | ±0,00 % | |
| 6 | HELLOFRESH SE INH O.N. Hauptdiskussion | +0,07 % | |
| 7 | VONOVIA Hauptdiskussion | +0,53 % | |
| 8 | RHEINMETALL Hauptdiskussion | +0,26 % | |
| 9 | Renk Group.......der Weg zum Erfolg | -0,34 % | |
| 10 | Diginex | ±0,00 % | Alle Diskussionen |